These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 929508)

  • 21. [The determination of platelet factor 3 using hirudin].
    Wamhoff D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1975; 102(1):82-7. PubMed ID: 50972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The platelet defect in alcoholism.
    Cowan DH
    Ann N Y Acad Sci; 1975 Apr; 252():328-41. PubMed ID: 1056733
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of oral contraceptive use on platelet prothrombin converting (platelet factor 3) activity.
    Leff B; Henriksen RA; Owen WG
    Thromb Res; 1979; 15(5-6):631-8. PubMed ID: 494168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased platelet aggregation, Ca2+ and Mg2+ ATPase and platelet factor 3 activities in patients with Wilson disease.
    Cohen AM; Brettbart H; Creter D; Levinsky H; Frydman M; Djaldetti M
    Haematologica; 1984; 69(3):263-71. PubMed ID: 6147299
    [No Abstract]   [Full Text] [Related]  

  • 25. [Thrombocyte functions in diabetics with proliferative retinopathy and in normal persons].
    Peters KM; Reuter HD
    Med Klin (Munich); 1986 Jun; 81(14):477-80. PubMed ID: 3785033
    [No Abstract]   [Full Text] [Related]  

  • 26. [Inhibition of primary hemostasis and the coagulative pathway].
    Di Micco B; Cinque MR; Pagliara E; Ciccone S; Messina MF; De Felice MG; Del Guercio R; Marcacci M
    Pediatria (Napoli); 1979 Jun; 87(2):219-26. PubMed ID: 44903
    [No Abstract]   [Full Text] [Related]  

  • 27. Release of platelet factor 4 (PF4) measured by a polybrene assay in response to in vitro platelet damage.
    Levine SP; Wohl H; Marzec U; Bernstein EF; Kroener J
    Thromb Res; 1977 Jan; 10(1):1-10. PubMed ID: 850894
    [No Abstract]   [Full Text] [Related]  

  • 28. [Blood serum antiplatelet activity in acute leukemia and idiopathic thrombopenia studied with the aid of the platelet factor 3 availability test].
    Podolak-Dawidziak M
    Acta Haematol Pol; 1979 Oct; 10(4):251-7. PubMed ID: 539351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet antibody determination using platelet factor 3 assay in thrombocytopenic patients.
    Chong LL
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1986 Nov; 19(4):233-7. PubMed ID: 3816366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunologic methods for clinical and experimental usage.
    Messmore HL; Fareed J; Kniffin J; Squillaci G; Walenga J
    Ann N Y Acad Sci; 1981; 370():785-97. PubMed ID: 7023331
    [No Abstract]   [Full Text] [Related]  

  • 31. Purification and characterization of human and bovine platelet factor 4.
    Wu VY; Walz DA; McCoy LE
    Prep Biochem; 1977; 7(6):479-93. PubMed ID: 343096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Potassium, magnesium, copper, manganese and cobalt salts of aspartic acid on platelet factor 3 availability (author's transl)].
    Reuter HD; Schröter G
    Arzneimittelforschung; 1980; 30(12):2106-8. PubMed ID: 7194069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Action of phospholipases on the phosphatidylcholine exchange protein from beef liver.
    Kamp HH; Sprengers ED; Westerman J; Wirtz KW; Van Deenen LL
    Biochim Biophys Acta; 1975 Sep; 398(3):415-23. PubMed ID: 1174523
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of carbamoylpiperidine and nipecotoylpiperazine analogs on ADP-stimulated human thrombocyte aggregation and platelet factor 3 availability.
    Dillingham EO; Lasslo A; Gollamudi R; Bond SE; Carter-Burks G
    Res Commun Chem Pathol Pharmacol; 1990 Feb; 67(2):179-99. PubMed ID: 2333408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of prostacyclin derivatives on platelet factor 3 availability.
    Skopál J; Kovács M; Stadler I; Galambos G; Kovács G
    Thromb Res; 1987 Jul; 47(1):117-21. PubMed ID: 3310323
    [No Abstract]   [Full Text] [Related]  

  • 36. [Effect and therapy in the control of thrombocyte-induced hemorrhage with phospholipids (exemplified by Fibraccel)].
    Tilsner V
    Beitr Infusionther Klin Ernahr; 1986; 15():187-95. PubMed ID: 3753408
    [No Abstract]   [Full Text] [Related]  

  • 37. Impairment of platelet adhesiveness and platelet factor 3 activity in cyanotic congenital heart disease.
    Bhargava M; Sanyal SK; Thapar MK; Kumar S; Hooja V
    Acta Haematol; 1976; 55(4):216-23. PubMed ID: 816160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved radioimmunoassay of platelet factor 4 and beta-thromboglobulin in plasma.
    Brown TR; Ho TT; Walz DA
    Clin Chim Acta; 1980 Feb; 101(2-3):225-33. PubMed ID: 6153585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification of blood coagulation factors II, VII, IX and X from bovine citrated plasma.
    Reekers P; Hemker HC
    Haemostasis; 1972; 1(1):2-22. PubMed ID: 4668761
    [No Abstract]   [Full Text] [Related]  

  • 40. [Changes in blood coagulating and thrombocytic factors in leukemia].
    Stepanian MA; Eliian LN; Osipova EN; Pogosian AS; Muradian LB
    Zh Eksp Klin Med; 1978; 18(3):86-90. PubMed ID: 278416
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.